← Atlas Theme · spans 1 topics
Geopolitical rivalry forces sovereign regulators to overhaul early-stage clinical trial trial structures.
To prevent clinical research and pharmaceutical pipelines from migrating to global competitors like China, home states are introducing expedited pilot pathways and pilot programs.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
HHS and FDA Formally Launch "Operation Trailblazer" to Sweepingly Reform U.S. Clinical Trials and Counter China HHS launched a coordinated structural overhaul to reduce clinical trial wait times in order to directly counter Chinese clinical dominance.
Science & Health
HHS and FDA Clinical Trials Reform: "Operation Trailblazer" and the Proposed Expedited-IND Pilot Program To reverse a trend of early-stage trials migrating to China, the FDA proposed a fast-tracked pilot model to significantly contract domestic IND timelines.